Freenome, a Palo Alto, CA-based developer of early-detection cancer tests, raised $5.6m in seed funding.
The round was led by Andreessen Horowitz, with participation from Founders Fund, Data Collective Venture Capital, and Third Kind Venture Capital, among others.
The company intends to use the funds to continue to advance its tech platform in partnership with leading institutions.
Led by Gabriel Otte (CEO), Charlie Roberts (Executive Chairman), Riley Ennis (COO), Michael Otte (CTO) and Adam Drake (Chief of Bioinformatics), Freenome has developed a tech platform that merges genomics research and computational expertise to dynamically collect genetic material floating in the blood (cell-free) derived from cells in the body to develop early detection tests for cancer.
FinSMEs
10/06/2016